Disease Modifying Anti-rheumatics (DMARD) (+ 25qs) Flashcards
OA - fill in about colexcicb
State the treatment pyramid for RA:
Pain management: [2]
First line disease treament (Mild RA): [2]
Second line disease treatment (moderate RA) [2]
Second line disease management: (severe RA) [2]
Pain management: NSAID & Opioids
First line: Methotrexate & 2nd line DMARD
Second line disease treatment (moderate RA) Methotrexate & TNF-inhibitor
Second line disease management: (severe RA) Methotrexate & Rituximab
If have a flair of RA which drug might be used as adjunct therapy? [1]
Oral corticosteroid pulse (e.g. prednisilone)
How may you start DMARD treatment if have severe RA? [2]
Start with high dose and taper down once under control
OR
Add prednisilone
State 3 reasons why may not prescribe methotrexate [3]
Liver damage (methotrexate metabolised in liver)
Pregnant
Co-morbidities
State two factors that DMARDs improve [2]
What does DMARD not improve? [1]
Improves:
* early improves number of swollen
* improves radiographic progression
No effect:
* the patients fatigue severity
Explain MoA of methotrexate [4]
How is it administered? [1]
Oral dose (can change to subcut. or IM)
MoA:
* Folic acid antagonist which will limits DNA and RNA synthesis by inhibiting dihydrofolate reductase and thymidylate synthetase
* Causes a reduction in purine synthesis
* Induce ROS
* Causes activation of apoptosis
* Inhibits pro-inflam cytokines IL-1 & NF-kB
State three side effects of methotrexate [2]
Can cause liver problems
Can affect blood count
Hair
Describe MoA of Sulfasalazine [5]
Mode of action in RA not well understood:
* Metabolised in the colon by gut bacteria to 5-ASA
* 5-ASA stays in large intestine lamina propria and has local anti-inflammatory actions
* Supresses generation of superoxide radicals and cytokine production by inflammatory cells
* IL8 decreased in synovial fluid and decreased production of IgM and IgG, and decreased angiogenesis
* Inhibits IL-1 and TNF-a
Describe the MoA of Hydroxychloroquine [2]
- Accumulates in lysosomes increasing the pH decreasing protein modifications
- Blocks Toll-like receptor 9 which recognises DNA containing immune complexes decreases activation of dendritic cells: less autoantobodies produced
Describe MoA of Leflunomide [3]
Pro-drug: gets metabolised in liver
Inhibits dihydroorotate dehydrogenase (DHODH) and therefore stops pyrimidine biosynthesis
Reduces pro-inflammatory cytokines: IL-1, TNF-A and IL-6
Blocks T cell proliferation
leflunomide has a similar mechanism of action to
Etanercept
Infliximab
Methotrexate
Sulfasalazine
Hydroxychloroquine
Methotrexate
Both block block on RNA and DNA synthesis via different, synergestic pathways
State which of the following blocks pyrimidine or purine synthesis:
Methotrexate
Leflunomide
Methotrexate: stops purine synthesis
Leflunomide: stops pyrimidine synthesis
Name two TNF-a blockers for RA [2]
Etanercept
Infliximab
Explain MoA of Etanercept:
What is etanercept a fusion protein for? [1]
What is etanercept Fc for? [1]
When TNF-a is released: finds receptors on cells, activates and causes signal transduction
Etanercept is a fusion protein human TNF receptor 2 and Fc human IgG.
Etanercept binds to TNF-a before TNF-a can get to cell and cause inflammatory, signalling
Describe MoA of Infliximab [1]
Monoclonal antibody against TNFα
Which of the following acts quicker:
Infliximab
Etanercept
Infliximab
Etanercept
Infliximab often prescribed alongside which drug? [1]
Infliximab and methotrexate
Name another TNF-inhibitor used in RA [1]
Adalimumab
Name a Human recombinant IL-1 receptor antagonist to treat RA
Anakinra
Describe efficacy of IL-1 antagonists c.f TNF-alpha blockers
IL-1 receptors antagonists are not as effective in RA as TNF-alpha blockers
Despite good efficacy, why is Anakina not as commonly prescribed for RA? [1]
Requires subcut daily injections
Describe MoA of Anakinra [1]
Monoclonal antibody that is a IL-1 antagonist
Describe MoA of Rituximab
Monoclonal antibody that targets CD20 on B cells
Means B cell can’t become activated
Destroys normal and malignant B cells